Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)-Reference-Cited by-同舟云学术

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)

Published:2012-05-28 Issue:6 Volume:18 Page:990-996
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Young G.¹,Cooper D. L.²,Gut R. Z.²,

Affiliation:

1. Children's Center for Cancer and Blood Disorders; Children's Hospital Los Angeles; University of Southern California Keck School of Medicine; Los Angeles; CA

2. Novo Nordisk Inc.; Princeton; NJ; USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2012.02864.x/fullpdf

Reference15 articles.

1. Mechanism of action of factor VIIa in the treatment of coagulopathies;Hedner;Semin Thromb Hemost,2006

2. Clinical experience with recombinant factor VIIa;Lusher;Blood Coagul Fibrinolysis,1998

3. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group;Lusher;Haemophilia,1998

4. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors;Key;Thromb Haemost,1998

5. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison;Young;Haemophilia,2008

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

2. Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa;Journal of Thrombosis and Haemostasis;2022-08

3. Transfusion Therapy in Specific Clinical Situations;Transfusion Medicine;2021-03-02

4. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors;Haemophilia;2019-09-05

5. A case of severe hemophilia A with inhibitor suffered from difficult hemostatic management after tooth extraction;Japanese Journal of Oral and Maxillofacial Surgery;2019-08-20